Cytokine release syndrome, grade 2
ICD-10 D89.832 is a billable code used to indicate a diagnosis of cytokine release syndrome, grade 2.
Cytokine release syndrome (CRS) is a systemic inflammatory response that can occur following certain therapies, particularly immunotherapies such as CAR T-cell therapy or monoclonal antibodies. Grade 2 CRS is characterized by moderate symptoms that may include fever, fatigue, headache, myalgia, and mild hypotension. Patients may exhibit laboratory abnormalities such as elevated inflammatory markers (e.g., C-reactive protein, ferritin) and changes in blood cell counts. The syndrome results from the rapid release of cytokines into the bloodstream, leading to a cascade of inflammatory responses. In grade 2 CRS, symptoms are more pronounced than in grade 1 but do not require intensive medical intervention. Management typically involves supportive care, monitoring, and may include the use of corticosteroids or other immunosuppressive agents to mitigate symptoms. Understanding the grading of CRS is crucial for appropriate coding and treatment planning, as it impacts clinical decision-making and resource allocation.
Detailed clinical notes on patient symptoms, treatment history, and laboratory results.
Patients receiving CAR T-cell therapy or monoclonal antibodies experiencing CRS.
Ensure clear documentation of CRS grading and management strategies.
Comprehensive records of immune response assessments and cytokine levels.
Patients with autoimmune disorders undergoing treatment that may trigger CRS.
Document any pre-existing conditions that may influence CRS presentation.
Used when administering chemotherapy that may lead to CRS.
Document the drug administered, dosage, and patient response.
Oncology specialists should ensure accurate coding of chemotherapy-related complications.
Grade 2 CRS typically presents with moderate symptoms such as fever, fatigue, headache, myalgia, and mild hypotension, along with laboratory abnormalities like elevated inflammatory markers.
